Spots Global Cancer Trial Database for fruquintinib
Every month we try and update this database with for fruquintinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC | NCT06427005 | Fruquintinib S-1 Raltitrexed | Fruquintinib S-1 raltitrexed | 18 Years - | West China Hospital | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | NCT04948034 | Metastatic Colo... | Stereotactic Ab... Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer | NCT06102772 | Gastric Cancer | Adebrelimab，Fru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） | NCT05025631 | Colorectal Canc... | Fruquintinib | 65 Years - | Sichuan University | |
| A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases | NCT06218888 | Colo-rectal Can... | Tislelizumab Fruquintinib Chidamide | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | NCT06347198 | Metastatic Colo... | Fruquintinib Sintilimab Inulin | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | NCT05842525 | Colorectal Canc... | intensive treat... Maintenance tre... | 18 Years - 75 Years | Hunan Cancer Hospital | |
| Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma | NCT05625737 | Stomach Neoplas... | Fruquintinib Sintilimab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Fruquintinib DDI Study With P-gp and BCRP Substrates | NCT05368805 | Metastatic Colo... | Fruquintinib Dabigatran Etex... Rosuvastatin | 18 Years - 55 Years | Hutchmed | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma | NCT05941325 | Advanced or Unr... | fruquintinib Envafolimab | 12 Years - 70 Years | Shanghai 6th People's Hospital | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy | NCT06317298 | Renal Cell Carc... | Fruquintinib an... | 18 Years - 75 Years | Peking University First Hospital | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| A Phase Ib Study of Fruquintinib in 3rd Line mCRC | NCT01975077 | Colorectal Canc... | fruquintinib | 18 Years - 70 Years | Hutchmed | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | NCT05257122 | Advanced Pancre... | Fruquintinib | 18 Years - 80 Years | Fudan University | |
| Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer | NCT05659290 | Metastatic Colo... | Fruquintinib al... Bevacizumab plu... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | NCT02196688 | Colorectal Canc... | fruquintinib placebo | 18 Years - 75 Years | Hutchmed | |
| Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma | NCT05971199 | Hepatocellular ... | Fruquintinib Sintilimab Transcatheter a... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance | NCT06202599 | Bone Sarcoma Soft Tissue Sar... Refractory Tumo... | Fruquintinib | - | Peking University People's Hospital | |
| Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer | NCT05659290 | Metastatic Colo... | Fruquintinib al... Bevacizumab plu... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study | NCT06202417 | Colorectal Canc... Refractory Colo... Metastatic Colo... | Fruquintinib | - | Fudan University | |
| Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer | NCT06118762 | Metastatic Colo... | Fruquintinib | 18 Years - | The First Affiliated Hospital of Nanchang University | |
| TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer | NCT05993702 | TAS 102 Regorafenib Fruquintinib Gastrointestina... | regorafenib fruquintinib | 18 Years - 75 Years | China Medical University, China | |
| Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer | NCT04431791 | Colorectal Canc... | Regorafenib Fruquintinib | - | Peking University | |
| Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma | NCT05122091 | Gastric Cancer GastroEsophagea... Fruquintinib SOX | Fruquintinib + ... | 18 Years - 75 Years | Guangxi Medical University | |
| Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study | NCT06234007 | Locally Advance... | Fruquintinib, A... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer | NCT06094868 | Gastric Cancer | Fruquintinib | 18 Years - 75 Years | Second Affiliated Hospital of Nanchang University | |
| Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | NCT05914610 | Gastric Cancer | Envolimab Fruquintinib Oxaliplatin Tegafur | 18 Years - 75 Years | Fujian Medical University | |
| Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | NCT06347198 | Metastatic Colo... | Fruquintinib Sintilimab Inulin | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study | NCT06202417 | Colorectal Canc... Refractory Colo... Metastatic Colo... | Fruquintinib | - | Fudan University | |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | NCT05565417 | Non Small Cell ... Head and Neck S... Triple Negative... Cutaneous Squam... Hormone Recepto... Small Bowel Can... Esophageal Canc... Colorectal Canc... Diffuse Large B... Hodgkin Lymphom... Burkitt Lymphom... Follicular Lymp... | IMT-009 Fruquintinib | 18 Years - | Immunitas Therapeutics | |
| Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | NCT01645215 | Tumor | Fruquintinib | 18 Years - 70 Years | Hutchmed | |
| Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | NCT05771181 | Colorectal Canc... Microsatellite ... | Vitamin E Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Fruquintinib in the Treatment of Soft Tissue Sarcoma | NCT05142631 | Soft Tissue Sar... | Fruquintinib | 18 Years - | Fudan University | |
| Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | NCT04296019 | Colo-rectal Can... | Fruquintinib | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | NCT02691299 | NSCLC | Fruquintinib Placebo | 18 Years - 75 Years | Hutchmed | |
| A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients | NCT06169202 | Fruquintinib Irinotecan Capecitabine Gastrointestina... | fruquintinib Irinotecan Capecitabine | 18 Years - 75 Years | China Medical University, China | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | NCT05771181 | Colorectal Canc... Microsatellite ... | Vitamin E Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | NCT05954429 | Colorectal Canc... | serplulimab Fruquintinib | 18 Years - | Fudan University | |
| Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | NCT03976856 | Metastatic Non-... | GB226 Fruquintinib | 18 Years - 75 Years | Genor Biopharma Co., Ltd. | |
| Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | NCT03977090 | Metastatic Colo... | Geptanolimab In... Fruquintinib | 18 Years - 75 Years | Genor Biopharma Co., Ltd. | |
| Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | NCT05447715 | Metastatic Colo... | Fruquintinib | 18 Years - 100 Years | Fudan University | |
| A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | NCT02590965 | Non-small Cell ... | Fruquintinib Placebo | 18 Years - 75 Years | Hutchmed | |
| Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | NCT06255379 | Metastasis Colo... Colon Cancer Rectal Cancer | Fuquinitinib+Te... | 18 Years - 75 Years | Guangzhou University of Traditional Chinese Medicine | |
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC | NCT06427005 | Fruquintinib S-1 Raltitrexed | Fruquintinib S-1 raltitrexed | 18 Years - | West China Hospital | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer | NCT05795296 | Stomach Neoplas... | Fruquintinib Sintilimab | 18 Years - 80 Years | RenJi Hospital | |
| Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | NCT05447715 | Metastatic Colo... | Fruquintinib | 18 Years - 100 Years | Fudan University | |
| : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors | NCT03903705 | Advanced Solid ... | Fruquintinib in... | 18 Years - 75 Years | Hutchmed | |
| Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | NCT05914610 | Gastric Cancer | Envolimab Fruquintinib Oxaliplatin Tegafur | 18 Years - 75 Years | Fujian Medical University | |
| A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | NCT05257122 | Advanced Pancre... | Fruquintinib | 18 Years - 80 Years | Fudan University | |
| Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | NCT05435313 | Colorectal Canc... | HAIC Fruquintinib Tislelizumab Raltitrexed Oxaliplatin Irinotecan | 18 Years - 75 Years | Fudan University | |
| Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed | NCT06102759 | Gastric Cancer | Adebrelimab，Fru... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | NCT05406206 | Advanced Colore... Liver Metastasi... | Fruquintinib Hepatic Arteria... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | NCT03977090 | Metastatic Colo... | Geptanolimab In... Fruquintinib | 18 Years - 75 Years | Genor Biopharma Co., Ltd. | |
| Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer | NCT05643677 | Gastric Cancer | Fruquintinib Irinotecan | 18 Years - | Fujian Medical University | |
| Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | NCT06255379 | Metastasis Colo... Colon Cancer Rectal Cancer | Fuquinitinib+Te... | 18 Years - 75 Years | Guangzhou University of Traditional Chinese Medicine | |
| Fruquintinib Combined With TAS102 for Advanced Gastric Cancer | NCT06102785 | Gastric Cancer | Fruquintinib, T... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | NCT03684967 | Lung Cancer | Fruquintinib | 18 Years - | Hutchmed | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT | NCT05763927 | Rectal Cancer | Fruquintinib Toripalimab Short-course ra... TME | 18 Years - 75 Years | West China Hospital | |
| A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | NCT05511051 | Colorectal Canc... | Fruquintinib HAIC | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | NCT02590965 | Non-small Cell ... | Fruquintinib Placebo | 18 Years - 75 Years | Hutchmed | |
| Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer | NCT05795296 | Stomach Neoplas... | Fruquintinib Sintilimab | 18 Years - 80 Years | RenJi Hospital | |
| Fruquintinib Combined With TAS102 for Advanced Gastric Cancer | NCT06102785 | Gastric Cancer | Fruquintinib, T... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC | NCT05292417 | Colorectal Neop... | hypofractionati... sintilimab GM-CSF Fruquintinib | 18 Years - 80 Years | The First Affiliated Hospital of Xiamen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
